Market Overview:
The global Orodispersible Tablets Market is estimated to be valued at US$ 9.29 billion in 2022 and is expected to exhibit a CAGR of 9.3% over the forecast period of 2023-2030, as highlighted in a new report published by Coherent Market Insights. This market is witnessing significant growth due to the increasing prevalence of chronic diseases, the rising global geriatric population, and the convenience offered by orodispersible tablets in drug administration.
Market Key Trends:
One of the key trends in the orodispersible tablets market is the growing preference for patient-friendly dosage forms. With the increasing number of elderly patients and individuals with swallowing difficulties, there is a rising demand for pharmaceutical products that are easy to use and consume. Orodispersible tablets, also known as melt-in-mouth tablets, dissolve quickly in the mouth without the need for water, making them an ideal option for patients who have difficulty swallowing traditional tablets.
For instance, AstraZeneca PLC recently launched their orodispersible tablet formulation of Crestor (rosuvastatin) in Europe. This formulation provides an alternative dosage form for patients who struggle with swallowing, enhancing patient compliance and convenience.
Segment Analysis:
The orodispersible tablets market is segmented based on the therapeutic class. The cardiovascular segment dominates the market due to the high prevalence of cardiovascular diseases globally and the increasing adoption of orodispersible tablets for cardiac medications. Within this segment, antihypertensive drugs sub-segment holds a significant market share due to the increasing prevalence of hypertension and the need for effective drug delivery options.
Key Takeaways:
The Global Orodispersible Tablets Market Growth is expected to witness high, exhibiting a CAGR of 9.3% over the forecast period. This growth can be attributed to increasing patient preference for convenient drug delivery, particularly among the elderly and individuals with swallowing difficulties. The market is driven by factors such as the rising prevalence of chronic diseases and the convenience offered by orodispersible tablets.
In terms of regional analysis, North America is expected to be the fastest-growing and dominating region in the orodispersible tablets market. This can be attributed to the presence of a well-established healthcare infrastructure, high adoption rate of new technologies, and increasing geriatric population in the region.
Key players operating in the global orodispersible tablets market include AstraZeneca PLC, GlaxoSmithKline PLC, Novartis International AG, Johnson & Johnson Services, Inc., Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Pfizer Inc., Cipla Limited, Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Lupin Pharmaceuticals, Inc., Torrent Pharmaceuticals Ltd., F. Hoffmann-La Roche Ltd., Eisai Co., Ltd., and Takeda Pharmaceutical Company Limited.
With the growing demand for patient-friendly dosage forms and the increasing prevalence of chronic diseases, the global orodispersible tablets market is poised for significant growth in the coming years. The convenience and ease of administration offered by orodispersible tablets make them a preferred choice for patients, leading to increased market adoption and expansion.
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc.